Skip to main navigation Skip to search Skip to main content

A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response

  • Teri Pearlstein
  • , E. Spurell
  • , L. A. Hohlstein
  • , V. Gurney
  • , J. Read
  • , C. Fuchs
  • , M. B. Keller
    • Brown University
    • Women and Infants Hospital of Rhode Island
    • L. Hill Inn R. Eating Disorder Prog.

    Research output: Contribution to journal › Article › peer-review

    69 Scopus citations

    Abstract

    Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.

    Original languageEnglish
    Pages (from-to)147-151
    Number of pages5
    JournalArchives of Women's Mental Health
    Volume6
    Issue number2
    DOIs
    StatePublished - Apr 2003

    Keywords

    • Binge eating disorder
    • Fluvoxamine
    • Placebo

    Fingerprint

    Dive into the research topics of 'A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response'. Together they form a unique fingerprint.

    Cite this